共 50 条
- [41] In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinomaGYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 430 - 438Han, ChanheePerrone, EmanueleZeybek, BurakBellone, StefaniaTymon-Rosario, JoanAltwerger, GaryMenderes, GuldenFeinberg, JacquelineHaines, KaitlinKarger, Mariana Espinal MullerBianchi, AnnaZammataro, LucaManzano, AranzazuBonazzoli, ElenaManara, PaolaBuza, NataliaHui, PeiRatner, ElenaSilasi, Dan-ArinHuang, Gloria S.Azodi, MasoudSchwartz, Peter E.Lopez, SalvatoreSantin, Alessandro D.
- [42] EFFICACY AND ADDITIONAL MECHANISM OF ACTION OF SACITUZUMAB GOVITECAN, A TROP-2 DIRECTED ANTIBODY-DRUG CONJUGATE, IN PRECLINICAL MODELS OF NON-MUSCLE INVASIVE BLADDER CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1262 - A1262Chou, Chih-ChienKornyeyev, DmytroYang, BeckyOrf, JessicaSun, Hai-LingDave, RutwijLai, YurongPapalia, GiuseppeCardillo, ThomasScholler, Nathalie
- [43] Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)ONCOTARGET, 2015, 6 (26) : 22496 - 22512Goldenberg, David M.Cardillo, Thomas M.Govindan, Serengulam V.Rossi, Edmund A.Sharkey, Robert M.
- [44] The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan-effectiveness, pitfalls and promisesANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (09)Guerra, EmanuelaAlberti, Saverio
- [45] BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive gastric cancerEUROPEAN JOURNAL OF CANCER, 2018, 103 : E50 - E51Yu, J. C.Tang, W.Deng, X.Ou, Z.Gan, J.Dong, Q.Tan, B.Lu, L.Chen, B.Bao, C.Thomas, B.Li, S.
- [46] A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab EmtansineMOLECULAR CANCER THERAPEUTICS, 2019, 18 (10) : 1721 - 1730Le Joncour, VadimMartins, AnaPuhka, MaijaIsola, JormaSalmikangas, MarkoLaakkonen, PirjoJoensuu, HeikkiBarok, Mark
- [47] BAT8001, a potent anti-HER2 antibody-drug conjugate with a novel stable linker for the treatment of HER2-positive breast cancerCANCER RESEARCH, 2019, 79 (04)Tang, W.Deng, X.Ou, Z.Gan, J.Dong, Q.Tan, B.Lu, L.Chen, B.Bao, C.Li, S.Thomas, B.Yu, J-C
- [48] DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistanceINTERNATIONAL JOURNAL OF CANCER, 2017, 141 (08) : 1682 - 1689Takegawa, NaokiNonagase, YoshikaneYonesaka, KimioSakai, KazukoMaenishi, OsamuOgitani, YusukeTamura, TakaoNishio, KazutoNakagawa, KazuhikoTsurutani, Junji
- [49] OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer ModelsMOLECULAR CANCER THERAPEUTICS, 2025, 24 (02) : 163 - 175Li, Wan-FenChiang, Ming-FengWeng, Hao-ChengYang, Jhih-JieWu, Hsin-ShanWu, Szu-YuChen, Yu-JungLu, Chi-HuanTu, Jyy-ShiuanHsu, Ren-YuShia, Chi-ShengHuang, Teng-YiLai, Ming-Tain
- [50] Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian CancerFRONTIERS IN ONCOLOGY, 2020, 10Perrone, EmanueleLopez, SalvatoreZeybek, BurakBellone, StefaniaBonazzoli, ElenaPelligra, SilviaZammataro, LucaManzano, AranzazuManara, PaolaBianchi, AnnaBuza, NataliaTymon-Rosario, JoanAltwerger, GaryHan, ChanheeMenderes, GuldenRatner, ElenaSilasi, Dan-ArinAzodi, MasoudHui, PeiSchwartz, Peter E.Scambia, GiovanniSantin, Alessandro D.